Stock Track | Progyny (PGNY) Surges 7.74% in Pre-Market on Strong Q4 Results and Growth Prospects

Stock Track

28 Feb

Progyny (PGNY) stock soared 7.74% in the pre-market session on Friday, driven by the company's robust fourth-quarter 2024 earnings and positive outlook for continued growth.

The fertility benefits provider reported impressive financial results for Q4 2024:

Revenue increased 11% year-over-year to $298.4 million, exceeding guidance.
Adjusted EBITDA rose 10% to $47.5 million, with a margin of 15.9%.
Achieved record quarterly ART cycle volume of over 15,800 cycles.

For the full year 2024, Progyny's revenue grew 7% to $1.17 billion, marking its ninth consecutive year of growth. The company's strong performance was driven by several factors:

Added over 80 new clients, including its first national health plan partner, Cigna.
Expanded services offerings in areas like maternity, postpartum, and menopause.
Retained 99% of existing clients, reflecting high satisfaction.
Continued investments in digital assets and product development.

While Progyny expects variability in member engagement and the loss of a large client (Amazon) in 2025, the company remains optimistic about its growth prospects. It plans to expand its global offerings and leverage strategic partnerships to drive further adoption of its comprehensive fertility solutions.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1121131150"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1121131150\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1121131150?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-28 20:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1121131150","market":"hk","top_or_hot":-1,"title":"Stock Track | Progyny (PGNY) Surges 7.74% in Pre-Market on Strong Q4 Results and Growth Prospects","media":"Stock Track","content":"<p>Progyny (PGNY) stock soared 7.74% in the pre-market session on Friday, driven by the company's robust fourth-quarter 2024 earnings and positive outlook for continued growth.</p>\n\n<p>The fertility benefits provider reported impressive financial results for Q4 2024:</p>\n<ul>\n<li>Revenue increased 11% year-over-year to $298.4 million, exceeding guidance.</li>\n<li>Adjusted EBITDA rose 10% to $47.5 million, with a margin of 15.9%.</li>\n<li>Achieved record quarterly ART cycle volume of over 15,800 cycles.</li>\n</ul>\n\n<p>For the full year 2024, Progyny's revenue grew 7% to $1.17 billion, marking its ninth consecutive year of growth. The company's strong performance was driven by several factors:</p>\n<ul>\n<li>Added over 80 new clients, including its first national health plan partner, Cigna.</li>\n<li>Expanded services offerings in areas like maternity, postpartum, and menopause.</li>\n<li>Retained 99% of existing clients, reflecting high satisfaction.</li>\n<li>Continued investments in digital assets and product development.</li>\n</ul>\n\n<p>While Progyny expects variability in member engagement and the loss of a large client (Amazon) in 2025, the company remains optimistic about its growth prospects. It plans to expand its global offerings and leverage strategic partnerships to drive further adoption of its comprehensive fertility solutions.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Progyny (PGNY) Surges 7.74% in Pre-Market on Strong Q4 Results and Growth Prospects</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Progyny (PGNY) Surges 7.74% in Pre-Market on Strong Q4 Results and Growth Prospects\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-28 20:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Progyny (PGNY) stock soared 7.74% in the pre-market session on Friday, driven by the company's robust fourth-quarter 2024 earnings and positive outlook for continued growth.</p>\n\n<p>The fertility benefits provider reported impressive financial results for Q4 2024:</p>\n<ul>\n<li>Revenue increased 11% year-over-year to $298.4 million, exceeding guidance.</li>\n<li>Adjusted EBITDA rose 10% to $47.5 million, with a margin of 15.9%.</li>\n<li>Achieved record quarterly ART cycle volume of over 15,800 cycles.</li>\n</ul>\n\n<p>For the full year 2024, Progyny's revenue grew 7% to $1.17 billion, marking its ninth consecutive year of growth. The company's strong performance was driven by several factors:</p>\n<ul>\n<li>Added over 80 new clients, including its first national health plan partner, Cigna.</li>\n<li>Expanded services offerings in areas like maternity, postpartum, and menopause.</li>\n<li>Retained 99% of existing clients, reflecting high satisfaction.</li>\n<li>Continued investments in digital assets and product development.</li>\n</ul>\n\n<p>While Progyny expects variability in member engagement and the loss of a large client (Amazon) in 2025, the company remains optimistic about its growth prospects. It plans to expand its global offerings and leverage strategic partnerships to drive further adoption of its comprehensive fertility solutions.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PGNY","symbol_name":"Progyny","start_time":0,"source_url":"","article_id":"1121131150","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1121131150","pubTimestamp":1740744207,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Progyny  stock soared 7.74% in the pre-market session on Friday, driven by the company's robust fourth-quarter 2024 earnings and positive outlook for continued growth.The fertility benefits provider reported impressive financial results for Q4 2024:. Revenue increased 11% year-over-year to $298.4 million, exceeding guidance.Adjusted EBITDA rose 10% to $47.5 million, with a margin of 15.9%.Achieved record quarterly ART cycle volume of over 15,800 cycles.For the full year 2024, Progyny's revenue g","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PGNY":"Progyny"},"translate_title":"由于强劲的第四季度业绩和增长前景，股票跟踪Progyny(PGNY)盘前飙升7.74%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PGNY":1},"content_text":"Progyny (PGNY) stock soared 7.74% in the pre-market session on Friday, driven by the company's robust fourth-quarter 2024 earnings and positive outlook for continued growth.\nThe fertility benefits provider reported impressive financial results for Q4 2024:\n\nRevenue increased 11% year-over-year to $298.4 million, exceeding guidance.\nAdjusted EBITDA rose 10% to $47.5 million, with a margin of 15.9%.\nAchieved record quarterly ART cycle volume of over 15,800 cycles.\n\nFor the full year 2024, Progyny's revenue grew 7% to $1.17 billion, marking its ninth consecutive year of growth. The company's strong performance was driven by several factors:\n\nAdded over 80 new clients, including its first national health plan partner, Cigna.\nExpanded services offerings in areas like maternity, postpartum, and menopause.\nRetained 99% of existing clients, reflecting high satisfaction.\nContinued investments in digital assets and product development.\n\nWhile Progyny expects variability in member engagement and the loss of a large client (Amazon) in 2025, the company remains optimistic about its growth prospects. It plans to expand its global offerings and leverage strategic partnerships to drive further adoption of its comprehensive fertility solutions.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0}}}